Navigation Links
Shrinkage of prostate led to overestimation of cancer risk in trial
Date:9/12/2007

s among men in the finasteride group who were already harboring high-grade tumors at the start of the study.

"This is a very unusual situation -- though it will become more common in the future -- where the drug affects the marker we use to find the cancer," said Gann.

Using data from the Prostate Cancer Prevention Trial study, Gann and colleagues developed statistical models that took into account the size of the prostate gland and the number of needle cores that were taken during biopsy. In essence, the researchers compared finasteride to placebo among men with an equivalent number of needle samples per unit of gland volume.

The analyses showed that adjusting for changes in gland size due to the drug could account for all of the excess high-grade tumors.

"Once we did this adjustment, all the excess high-grade went away, and the effect of the drug on low-grade cancer was even stronger, as we would expect," Gann said.

"This drug may have been much better than people thought," Gann said, "and the fears about its impact on high grade tumors may have been exaggerated based on this bias alone."

However, he said, the findings must be interpreted cautiously, and the new results alone do not justify definitive changes in clinical practice or widespread use of the drug.

"Our goal is to improve scientific understanding of what happened in this very important and expensive trial."


'/>"/>

Contact: Sherri McGinnis Gonzlez
smcginn@uic.edu
312-996-8277
University of Illinois at Chicago
Source:Eurekalert

0

GOOD

Page: 1 2

Related medicine news :

1. High Levels of Protein Linked to Brain Shrinkage
2. Shrinkage Of Brain Size Linked To Chronic Pain
3. Stress the Main Cause of Brain Shrinkage in Old Age
4. Cancer Doctors Okays Controversial Prostate Therapy
5. More Accurate "PROSTATE CANCER" Test can save Unnecessary Biopsies
6. Radioactive Seeds used in Prostate Cancer treatment can migrate with the body
7. Better prostate cancer detection
8. Protective effects of tomatoes in prostate cancer
9. Early detection of prostate cancer
10. Prevention of Prostate Cancer
11. Low grade prostate cancer may be treated with mild treatment
Post Your Comments:
*Name:
*Comment:
*Email:
Other Medicine News:Health News:Study suggests blood test can help improve treatment outcomes for breast cancer patients 2Health News:CoorsTek Holds Grand Opening for Newest Facility in South Korea 2Health News:CoorsTek Holds Grand Opening for Newest Facility in South Korea 3Health News:Don't Wait for the Election to Plan Your Long-Term Healthcare, Insurance Leader Advises 2Health News:Chemo for Mesothelioma Offers Limited Survival Benefits 2Health News:dLife Launches the World's Largest and Most Comprehensive Online Food and Diabetic Recipe Search Tool 2Health News:Pharmasset Reports Financial Results for Quarter Ended March 31, 2008 2Health News:Pharmasset Reports Financial Results for Quarter Ended March 31, 2008 3Health News:Pharmasset Reports Financial Results for Quarter Ended March 31, 2008 4Health News:Pharmasset Reports Financial Results for Quarter Ended March 31, 2008 5Health News:Pharmasset Reports Financial Results for Quarter Ended March 31, 2008 6Health News:Pharmasset Reports Financial Results for Quarter Ended March 31, 2008 7Health News:Pharmasset Reports Financial Results for Quarter Ended March 31, 2008 8
Breaking Medicine Technology:FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 2FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 3FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 4The Army Awards Follow-On Contract for Autonomous Airway Management to Energid Technologies 2Express Scripts Launches Equity Offering to Finance Acquisition 47588 1Express Scripts Launches Equity Offering to Finance Acquisition 47588 2Express Scripts Launches Equity Offering to Finance Acquisition 47588 3Leading North American Emergency Medical Services Provider British Columbia Ambulance Service Selects NICE Inform for Improved Service 12409 1Leading North American Emergency Medical Services Provider British Columbia Ambulance Service Selects NICE Inform for Improved Service 12409 2Leading North American Emergency Medical Services Provider British Columbia Ambulance Service Selects NICE Inform for Improved Service 12409 3Leading North American Emergency Medical Services Provider British Columbia Ambulance Service Selects NICE Inform for Improved Service 12409 4Leading North American Emergency Medical Services Provider British Columbia Ambulance Service Selects NICE Inform for Improved Service 12409 5Prometheus Announces New Findings Regarding Patients at Risk for Celiac Disease at DDW 4513 1Prometheus Announces New Findings Regarding Patients at Risk for Celiac Disease at DDW 4513 2Prometheus Announces New Findings Regarding Patients at Risk for Celiac Disease at DDW 4513 3
Other Medicine Technology:Orchestra Therapeutics Announces New Phase II Clinical Data on,NeuroVax Demonstrating Marked Expansion of Regulatory T Cell,Populations in Patients With Multiple Sclerosis 2Orchestra Therapeutics Announces New Phase II Clinical Data on,NeuroVax Demonstrating Marked Expansion of Regulatory T Cell,Populations in Patients With Multiple Sclerosis 3Orchestra Therapeutics Announces New Phase II Clinical Data on,NeuroVax Demonstrating Marked Expansion of Regulatory T Cell,Populations in Patients With Multiple Sclerosis 4Orchestra Therapeutics Announces New Phase II Clinical Data on,NeuroVax Demonstrating Marked Expansion of Regulatory T Cell,Populations in Patients With Multiple Sclerosis 5Fractionated Radioimmunotherapy With (90)Y-epratuzumab in,Non-Hodgkin's Lymphoma Appears Safe and Active in a Phase I/II,Study 2Fractionated Radioimmunotherapy With (90)Y-epratuzumab in,Non-Hodgkin's Lymphoma Appears Safe and Active in a Phase I/II,Study 3Fractionated Radioimmunotherapy With (90)Y-epratuzumab in,Non-Hodgkin's Lymphoma Appears Safe and Active in a Phase I/II,Study 4Fractionated Radioimmunotherapy With (90)Y-epratuzumab in,Non-Hodgkin's Lymphoma Appears Safe and Active in a Phase I/II,Study 5